Carlsmed, Inc. (NASDAQ:CARL) Receives Average Rating of “Hold” from Brokerages

Carlsmed, Inc. (NASDAQ:CARL) has received a consensus rating of “Hold” from the five research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $19.3333.

Several analysts recently issued reports on the stock. The Goldman Sachs Group reduced their price target on shares of Carlsmed from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. BTIG Research reiterated a “buy” rating and set a $23.00 price objective on shares of Carlsmed in a report on Wednesday, May 6th. Truist Financial decreased their target price on shares of Carlsmed from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. Zacks Research upgraded shares of Carlsmed from a “strong sell” rating to a “hold” rating in a report on Thursday, March 26th. Finally, Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC grew its holdings in Carlsmed by 7.6% during the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after buying an additional 86,834 shares in the last quarter. KCM Capital Inc purchased a new position in Carlsmed during the 1st quarter worth $1,810,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Carlsmed in the 4th quarter worth $187,000. Millennium Management LLC raised its holdings in shares of Carlsmed by 521.2% in the fourth quarter. Millennium Management LLC now owns 128,970 shares of the company’s stock valued at $1,593,000 after purchasing an additional 108,208 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of Carlsmed by 0.8% in the fourth quarter. Russell Investments Group Ltd. now owns 160,238 shares of the company’s stock valued at $1,979,000 after purchasing an additional 1,292 shares during the last quarter.

Carlsmed Stock Performance

Shares of Carlsmed stock opened at $11.29 on Wednesday. The business has a 50-day simple moving average of $10.26 and a 200 day simple moving average of $11.99. Carlsmed has a one year low of $8.50 and a one year high of $17.19. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.88 and a quick ratio of 11.67. The firm has a market capitalization of $306.86 million and a price-to-earnings ratio of -4.50.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Carlsmed had a negative return on equity of 60.74% and a negative net margin of 57.76%.The firm had revenue of $16.12 million during the quarter. On average, research analysts anticipate that Carlsmed will post -1.35 earnings per share for the current fiscal year.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).